Noninvasive Prenatal Testing

NIPT genome analysis for predicting cancer

June 21, 2021

A retrospective analysis has found that comprehensive examination of shallow-sequenced, whole-genome cell-free DNA (cfDNA) allows for the incidental detection of maternal tumors, with relatively high precision.

Whole genome sequencing of cell-free DNA for NIPT

May 05, 2021

An analysis of a large cohort of patients who chose noninvasive prenatal testing (NIPT) as a screening method for fetal trisomy 21, 18, and 13 (T21, T18 and T13) and sex chromosome aneuploidies (SCA) concluded there were extremely high detection rates and exceptionally low false positive rates.

Economic impact of coverage expansion for NIPT

April 15, 2021

Expanding coverage for noninvasive prenatal testing (NIPT) through a performance-based, risk-sharing agreement (PBRSA) resulted in a significant increase in NIPT use, a significant decrease in conventional prenatal screening methods, and a negligible increase in per member per month (PMPM) cost at Harvard Pilgrim Health Care (HPHC) in New England.

Cost of cell-free DNA noninvasive testing for Down syndrome

March 09, 2021

A public health screening program for Down syndrome in Quebec, Canada, found that cell-free DNA noninvasive prenatal testing (NIPT) could be implemented at the same cost as the current screening program, according to computer simulations.

Expanding scope of noninvasive prenatal testing

February 23, 2021

“Our results can further inform the debate on the future uses of NIPT and future policy of its implementation,” said co-principal investigator Hazar Haidar, PhD, a lecturer in bioethics at Université du Québec à Montréal (UQAM), Montréal, Canada.